Abstract | OBJECTIVE: DESIGN: Thirty-one women with PCOS were recruited (mean age, 24.7+/-3.9 (s.e.) years; mean body mass index (BMI), 25.6+/-3.2 kg/m2). All women were treated with 4 mg rosiglitazone daily for 12 months. METHODS: RESULTS:
After treatment with rosigitazone there were significant decreases in serum testosterone (91.2+/-37.5 vs 56.1+/-21.8 ng/dl; P < 0.01) and fasting insulin concentrations (12.5+/-7.6 vs 8.75+/-4.03 microU/ml; P = 0.015). Insulin resistance indices were significantly improved after rosiglitazone treatment (P < 0.05). There were no significant changes in BMI, waist circumference, serum total cholesterol, low-density lipoprotein ( LDL)-cholesterol, FSH and LH levels. Hirsutism score was decreased significantly after treatment (10.8+/-1.8 vs 7.6+/-1.7; P < 0.05). Twenty-four of the women reverted to regular menstrual cycles. Levels of SHBG increased significantly after treatment (28.7+/-8.7 vs 48.4+/-11.2 nmol/l; P < 0.01). Serum hsCRP levels were decreased significantly after rosiglitazone treatment (0.25+/-0.1 vs 0.09+/-0.02 mg/dl; P = 0.006). There was also significant improvement in endothelium-dependent vascular responses after rosiglitazone treatment (9.9+/-3.9 vs 16.4+/-5.1%; P < 0.01). CONCLUSIONS:
|
Authors | Ilhan Tarkun, Berrin Cetinarslan, Erdem Türemen, Tayfun Sahin, Zeynep Cantürk, Baki Komsuoglu |
Journal | European journal of endocrinology
(Eur J Endocrinol)
Vol. 153
Issue 1
Pg. 115-21
(Jul 2005)
ISSN: 0804-4643 [Print] England |
PMID | 15994753
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Biomarkers
- Hormones
- Hypoglycemic Agents
- Thiazolidinediones
- Rosiglitazone
- C-Reactive Protein
|
Topics |
- Adult
- Biomarkers
(blood)
- Body Weight
- C-Reactive Protein
(metabolism)
- Endothelium, Vascular
(drug effects, metabolism)
- Female
- Hormones
(blood)
- Humans
- Hypoglycemic Agents
(administration & dosage)
- Insulin Resistance
- Muscle, Smooth, Vascular
(drug effects, metabolism)
- Obesity
- Polycystic Ovary Syndrome
(drug therapy, metabolism)
- Rosiglitazone
- Thiazolidinediones
(administration & dosage)
- Vasculitis
(metabolism, prevention & control)
|